Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. It is currently being investigated in adult patients with a history of atherosclerotic cardiovascular disease.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
NewAmsterdam TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe. It is being evaluated in Phase III clinical trial studies with patients for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
The net proceeds will be used for the development of TA-8995 (obicetrapib). It is a selective cholesteryl ester transfer protein inhibitor that potently decreases (LDL-C) as well as increases (HDL-C), which is used for the treatment of atherosclerotic Cardiovascular disease.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $173.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2024
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. It is currently being investigated in patients with early Alzheimer’s disease and at least one copy of the apolipoprotein E4 mutation.
Lead Product(s): Obicetrapib
Therapeutic Area: Neurology Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin therapy.
Lead Product(s): Obicetrapib
Therapeutic Area: Genetic Disease Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin therapy.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
TA-8995 (obicetrapib) is a next-generation, oral, low-dose CETP inhibitor that NewAmsterdam is developing to potentially overcome the limitations of current LDL-lowering treatments.
Lead Product(s): Obicetrapib
Therapeutic Area: Genetic Disease Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C, if approved. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin therapy.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Proceeds from this transaction will be used for three ongoing phase 3 trials, BROADWAY, BROOKLYN and PREVAIL, evaluating the effect of TA-8995 (obicetrapib) in patients with atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Frazier Healthcare Partners
Deal Size: $235.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 23, 2022
Details:
Obicetrapib (TA-8995) is an oral, low-dose and once-daily CETP inhibitor, initially in development for patients at high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combination with ezetimibe.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022